221 related articles for article (PubMed ID: 15705377)
1. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess.
Witchel SF; Kahsar-Miller M; Aston CE; White C; Azziz R
Fertil Steril; 2005 Feb; 83(2):371-5. PubMed ID: 15705377
[TBL] [Abstract][Full Text] [Related]
2. A variant of the glucocorticoid receptor gene is not associated with adrenal androgen excess in women with polycystic ovary syndrome.
Kahsar-Miller M; Azziz R; Feingold E; Witchel SF
Fertil Steril; 2000 Dec; 74(6):1237-40. PubMed ID: 11119758
[TBL] [Abstract][Full Text] [Related]
3. The role of heterozygosity for CYP21 in the polycystic ovary syndrome.
Witchel SF; Aston CE
J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1315-7. PubMed ID: 11117678
[TBL] [Abstract][Full Text] [Related]
4. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
5. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.
Knochenhauer ES; Cortet-Rudelli C; Cunnigham RD; Conway-Myers BA; Dewailly D; Azziz R
J Clin Endocrinol Metab; 1997 Feb; 82(2):479-85. PubMed ID: 9024240
[TBL] [Abstract][Full Text] [Related]
6. The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism.
Kelestimur F; Everest H; Dundar M; Tanriverdi F; White C; Witchel SF
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):205-8. PubMed ID: 19085698
[TBL] [Abstract][Full Text] [Related]
7. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations.
Escobar-Morreale HF; San Millán JL; Smith RR; Sancho J; Witchel SF
Fertil Steril; 1999 Oct; 72(4):629-38. PubMed ID: 10521100
[TBL] [Abstract][Full Text] [Related]
8. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
Moran C; Reyna R; Boots LS; Azziz R
Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555
[TBL] [Abstract][Full Text] [Related]
9. Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome.
Goodarzi MO; Antoine HJ; Azziz R
J Clin Endocrinol Metab; 2007 Jul; 92(7):2659-64. PubMed ID: 17426092
[TBL] [Abstract][Full Text] [Related]
10. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
11. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
12. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.
Admoni O; Israel S; Lavi I; Gur M; Tenenbaum-Rakover Y
Clin Endocrinol (Oxf); 2006 Jun; 64(6):645-51. PubMed ID: 16712666
[TBL] [Abstract][Full Text] [Related]
13. DHEA, DHEAS and PCOS.
Goodarzi MO; Carmina E; Azziz R
J Steroid Biochem Mol Biol; 2015 Jan; 145():213-25. PubMed ID: 25008465
[TBL] [Abstract][Full Text] [Related]
14. Ovarian and adrenal hyperandrogenism.
Carmina E
Ann N Y Acad Sci; 2006 Dec; 1092():130-7. PubMed ID: 17308139
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Gambineri A; Vicennati V; Genghini S; Tomassoni F; Pagotto U; Pasquali R; Walker BR
J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
[TBL] [Abstract][Full Text] [Related]
16. Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype.
Louwers YV; de Jong FH; van Herwaarden NA; Stolk L; Fauser BC; Uitterlinden AG; Laven JS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3848-55. PubMed ID: 23861462
[TBL] [Abstract][Full Text] [Related]
17. CYP21A2 mutations in women with polycystic ovary syndrome (PCOS).
Settas N; Dracopoulou-Vabouli M; Dastamani A; Katsikis I; Chrousos G; Panidis D; Dacou-Voutetakis C
Horm Metab Res; 2013 May; 45(5):383-6. PubMed ID: 23386413
[TBL] [Abstract][Full Text] [Related]
18. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome.
Ujvari D; Hulchiy M; Calaby A; Nybacka Å; Byström B; Hirschberg AL
Hum Reprod; 2014 Jul; 29(7):1526-35. PubMed ID: 24842895
[TBL] [Abstract][Full Text] [Related]
19. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
20. Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.
Goodarzi MO; Xu N; Azziz R
J Clin Endocrinol Metab; 2008 Jul; 93(7):2909-12. PubMed ID: 18445661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
